Neurocrine Drug: Real-World Risk Diverges From Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Neurocrine Biosciences is the subject of an analysis in STAT+'s 'Adam's Biotech Scorecard' examining the company's benefit-risk calculus for a rare-disease drug approved after a small clinical trial showed modest efficacy and manageable side effects.
- No deaths were reported in the original clinical trial, but physicians prescribing the drug widely after approval began noting a small number of patient deaths in real-world use.
- The drug's serious side effect frequency rose dramatically compared to the trial characterization, with some episodes severe enough to require hospitalization, according to the source.
Why it matters: For Neurocrine Biosciences and prescribers, the case illustrates how a drug approved on modest efficacy and manageable side effects in a small rare-disease trial can show a materially worse safety profile once used in larger, real-world patient populations.
Ask SkimNews
